Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab    GEN   DK0010272202

GENMAB (GEN)
Mes dernières consult.
Most popular
Report
Delayed Quote. Delayed  - 12/12 04:59:34 pm
1110 DKK   -6.17%
06:32p M&A "boom" dominates Europe share trading as oil leads gains
12:46p Sanofi investors hungry for drug progress and deal news
12/11 GENMAB : 2017 R&D Update
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
12/06/2017 12/07/2017 12/08/2017 12/11/2017 12/12/2017 Date
1192(c) 1165(c) 1194(c) 1183(c) 1110 Last
383 204 228 943 246 108 347 619 933 949 Volume
+2.41% -2.27% +2.49% -0.92% -6.17% Change
More quotes
Financials ( DKK)
Sales 2017 2 185 M
EBIT 2017 1 138 M
Net income 2017 957 M
Finance 2017 4 175 M
Yield 2017 -
Sales 2018 3 182 M
EBIT 2018 1 859 M
Net income 2018 1 851 M
Finance 2018 5 681 M
Yield 2018 0,01%
P/E ratio 2017 75,02
P/E ratio 2018 41,14
EV / Sales2017 31,2x
EV / Sales2018 21,0x
Capitalization 72 383 M
More Financials
Company
Genmab A/S operates as an international biotechnology company.The firm develops human antibody therapeutics for the treatment of cancer.Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.The company was founded by Lisa N. Drakeman and Jan G. 
More about the company
Surperformance© ratings of Genmab
Trading Rating : Investor Rating :
More Ratings
Latest news on GENMAB
06:32p M&A "boom" dominates Europe share trading as oil leads gains
12:46p Sanofi investors hungry for drug progress and deal news
12/11 GENMAB : 2017 R&D Update
12/11 GENMAB : 2017 R&D Update
12/06 GENESIS HEALTHCARE : Genmab to Hold 2017 R&D Update
12/04 GENMAB : to Hold 2017 R&D Update
12/01 MorphoSys grants I-Mab rights to CD38 mAb in China
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/29 GENMAB : Achieves USD 20 Million Milestone in Daratumumab Collaboration with Jan..
11/23 GENMAB A/S : - Data from Phase III ALCYONE Study of Daratumumab Accepted for Ora..
More news
Sector news : Bio Therapeutic Drugs
12/09 Tax-loss selling to pressure 2017's losers in December
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
11/27 Regeneron drops eye-drug combination as Novartis chases Eylea
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/30 YOUR DAILY PHARMA SCOOP : Valeant's B+L In India, TXMD's NDA Resubmission, Melin..
11/29 Genmab earns $20M milestone from Janssen on daratumumab advancement
11/14 Genmab earns $25M milestone from Janssen's first Darzalex sale in Japan
11/13 Genmab A/S ADR 2017 Q3 - Results - Earnings Call Slides
11/11 Genmab's (GNMSF) CEO Jan van de Winkel on Q3 2017 Results - Earnings Call Tra..
Chart GENMAB
Duration : Period :
Genmab Technical Analysis Chart | GEN | DK0010272202 | 4-Traders
Technical analysis trends GENMAB
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 1 475  DKK
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Jan G. J. van de Winkel President & Chief Executive Officer
Mats Gunnar Pettersson Chairman
David Andrew Eatwell Chief Financial Officer & Executive Vice President
Burton Gordon Malkiel Independent Director
Anders Gersel Pedersen Deputy Chairman
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB1.79%11 452
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
BLUEBIRD BIO INC172.12%9 249
EXELIXIS, INC.80.42%7 816